Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP815 in Advanced or Metastatic Solid Tumors With MAPK Pathway Alterations
NCT05557045Phase 1Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2022
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JZP815 in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 2 more (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Number of Participants With Dose-Limiting Toxicities up to 18 months, Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events up to 18 months and 2 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
JZP815
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT05557045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557045.